SG Americas Securities LLC Has $32.97 Million Stock Position in Baxter International Inc. $BAX

Key Points

• SG Americas Securities LLC increased its stake in Baxter by 477.6% in Q4 to 1,725,251 shares, a $32.97 million position representing about 0.34% of the company.
• Multiple analysts cut price targets recently and the consensus rating is a "Hold" with an average price target of $19.90 after downgrades from Goldman, Wells Fargo, Citi and Jefferies.
• Baxter missed Q earnings (EPS $0.44 vs. $0.53 est.) but beat on revenue ($2.97B), set FY2026 EPS guidance of $1.85–$2.05, and its stock trades near $17 with a negligible 0.2% dividend yield.

SG Americas Securities LLC increased its holdings in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 477.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,725,251 shares of the medical instruments supplier's stock after purchasing an additional 1,426,547 shares during the period. SG Americas Securities LLC owned 0.34% of Baxter International worth $32,970,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CoreFirst Bank & Trust acquired a new stake in shares of Baxter International in the second quarter valued at approximately $27,000. Imprint Wealth LLC acquired a new position in shares of Baxter International during the 3rd quarter worth approximately $27,000. CYBER HORNET ETFs LLC acquired a new position in shares of Baxter International during the 2nd quarter worth approximately $40,000. MUFG Securities EMEA plc bought a new stake in Baxter International in the 2nd quarter valued at $46,000. Finally, Motco raised its stake in Baxter International by 374.7% in the 3rd quarter. Motco now owns 3,071 shares of the medical instruments supplier's stock valued at $70,000 after acquiring an additional 2,424 shares during the period. Institutional investors own 90.19% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on BAX. The Goldman Sachs Group reduced their price objective on shares of Baxter International from $21.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, February 13th. Weiss Ratings restated a "sell (d)" rating on shares of Baxter International in a research note on Wednesday, January 21st. Wells Fargo & Company reduced their target price on shares of Baxter International from $21.00 to $19.00 and set an "equal weight" rating for the company in a report on Friday, December 12th. Citigroup decreased their price target on shares of Baxter International from $21.00 to $19.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 11th. Finally, Jefferies Financial Group lowered their price target on shares of Baxter International from $21.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, February 13th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $19.90.

Baxter International Price Performance

Baxter International stock opened at $17.13 on Thursday. The firm has a market cap of $8.82 billion, a PE ratio of -9.26, a price-to-earnings-growth ratio of 1.18 and a beta of 0.58. The company has a debt-to-equity ratio of 1.55, a current ratio of 2.31 and a quick ratio of 1.56. The stock's fifty day moving average price is $19.48 and its two-hundred day moving average price is $20.20. Baxter International Inc. has a one year low of $16.08 and a one year high of $34.51.

Baxter International (NYSE:BAX - Get Free Report) last released its earnings results on Thursday, February 12th. The medical instruments supplier reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.53 by ($0.09). The company had revenue of $2.97 billion for the quarter, compared to the consensus estimate of $2.82 billion. Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The business's revenue was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 earnings per share. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. As a group, research analysts expect that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Friday, February 27th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, February 27th. Baxter International's dividend payout ratio (DPR) is currently -2.16%.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.